6:01 PM
 | 
Oct 11, 2017
 |  BC Innovations  |  Emerging Company Profile

Chemo-proof T cells

Incysus's chemo-resistant γδ T cells could treat solid tumors

T cell therapies have shown unprecedented efficacy in hematologic malignancies, but haven’t produced the same results in solid tumors and have dangerous toxicities. By combining engineered, drug-resistant γδ T cells with chemotherapy, Incysus Ltd. has hit upon a strategy that may be safer and more effective against solid tumors than conventional T cell therapies.

The αβ T cells most T cell therapies use are antigen-specific and may not eliminate the entire tumor. Incysus relies on γδ T cells because they do not require antigen processing to detect target cells, and they penetrate and kill solid tumors more effectively than αβ cells.

“γδ T cells are like a bridge between the innate and adaptive immune response. They can kill like natural killer cells, then become antigen-presenting cells when activated,” said Incysus CEO and co-founder William Ho.

According to Ho, one reason T cell...

Read the full 696 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >